Which peer‑reviewed articles by William Makis are indexed in PubMed and what are their citations and abstracts?
Executive summary
A targeted review of the supplied reporting finds one PubMed‑indexed, peer‑reviewed article listing William Makis as an author: "Fenbendazole as an Anticancer Agent? A Case Series of Self‑Administration in Three Patients" published in Case Reports in Oncology in 2025, which is indexed on PubMed and has an associated retraction notice [1]. The available reporting does not provide a comprehensive PubMed bibliography for Makis, so claims of "100+ peer‑reviewed publications" appear in profiles and media but are not corroborated here with PubMed citations [2] [3] [4].
1. The single PubMed‑indexed paper identified and its citation
The paper identified in the provided sources is cited on PubMed as: Makis W, Baghli I, Martinez P. Fenbendazole as an Anticancer Agent? A Case Series of Self‑Administration in Three Patients. Case Rep Oncol. 2025 May 26;18:856‑863. doi: 10.1159/000546362. This entry is listed on PubMed and is available as a free PMC article [1].
2. What the PubMed record and reporting say about the article's abstract and content
The PubMed entry for the 2025 Case Reports in Oncology paper documents a case‑series describing three patients who self‑administered fenbendazole and reports observations relevant to tumor response; the article is available through PubMed Central for full text [1]. The supplied reporting notes that the case series compiles clinical observations of self‑administration and situates fenbendazole within literature on repurposed benzimidazole anthelmintics as potential anticancer agents [1]. The reporting does not reproduce the full abstract text, so this account relies on the PubMed listing and the article metadata as summarized in that listing [1].
3. Retraction and post‑publication developments
The PubMed record includes a retraction statement: the paper by Makis, Baghli, and Martinez was retracted (Case Rep Oncol. 2026 Jan 21;19:169; doi: 10.1159/000549387), and PubMed indexes that retraction alongside the original record [1]. This retraction is an essential part of the article’s current PubMed status and must frame interpretation of the original case‑series findings [1].
4. What the rest of the reporting shows — gaps and contested claims
Profiles, podcasts, and non‑peer‑reviewed pages repeatedly attribute "100+ peer‑reviewed publications" to Makis and promote protocols involving ivermectin, mebendazole and fenbendazole, but those sources (ResearchGate profile, Substack, podcasts, popular sites) are not PubMed listings and do not substitute for a PubMed index search [2] [3] [5] [6]. Independent watchdog commentary (Science Feedback) flags social‑media claims about "peer‑reviewed" protocols and questions their interpretation, indicating skepticism in parts of the scientific‑verification ecosystem [7]. The supplied reporting therefore documents widespread public promotion and controversy but does not supply additional PubMed citations for Makis beyond the 2025 case series [2] [6] [7] [3].
5. Reporting limitations and recommended next steps for verification
Given the provided sources, only the 2025 fenbendazole case‑series appears in PubMed with Makis as an author and that article now carries a retraction notice in PubMed [1]. The provided materials do not include a PubMed query list or additional PubMed IDs for other Makis publications, so it is not possible from these sources to enumerate other PubMed‑indexed Makis peer‑reviewed articles or reproduce their abstracts [2] [4]. A definitive answer requires (a) a direct PubMed author search for "Makis W" or "Makis William" and (b) retrieval of the PubMed records and abstracts for each returned item; those steps were not included in the reporting supplied here [1] [2].